Lehman CE, Khalil AA, Axelrod MJ, et al. - Because the insulin-like growth factor-1 receptor (IGF1R) has been involved in therapeutic resistance in head and neck squamous cell carcinoma (HNSCC), and small molecule tyrosine kinase inhibitors (TKIs) of IGF1R activity may have anticancer activity, therefore, the connection between survival and IGF1R expression was evaluated for oral cavity (OC) cancer, and the antitumor impacts of two IGF1R-TKIs, OSI-906 and BMS-754807, were assessed in HNSCC cell lines in vitro. To generate IGF1R expression-specific survival curves, clinical result information and tissue microarray immunohistochemistry were utilized. According to results, higher IGF1R expression was linked to poorer overall 5-year survival for patients with stage III/IV OCSCC. Investigators found that OSI-906 and BMS-754807 inhibit IGF1R activity in HNSCC cell lines with reduced prosurvival and proliferative signals as well as concurrent antiproliferative and proapoptotic effects. Such antagonists may be useful to current HNSCC therapies as adjuvants. Reverse phase protein array showed broad impacts of both drugs on canonical IGF1R signaling pathways and also inhibition of human epidermal growth factor receptor-3, Src, paxillin, and ezrin phosphorylation.